Current diagnosis of schizophrenia and bipolar disorder is challenging due to a complex range of symptoms. Early diagnosis is the key to vastly improved outcomes for patients.
The EU funded SCHIZDX (Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders) project has developed the first molecular test for the diagnosis of schizophrenia, VeriPsych®. The test is being marketed for diagnosis of first onset of schizophrenia.
Further details: Early diagnosis for psychiatric disorders